Literature DB >> 19211929

HIV-related liver disease: ARV drugs, coinfection, and other risk factors.

Massimo Puoti1, Paola Nasta, Francesca Gatti, Alessandro Matti, Katiela Prestini, Luciano Biasi, Giampiero Carosi.   

Abstract

Highly-active antiretroviral therapy (HAART) has proven remarkably effective for prolonging the life of patients with human immunodeficiency virus (HIV). However, while most HAART agents are safe, many have the potential to cause liver toxicity. Physicians must therefore consider the possibility of drug-induced liver injury in the management of HIV-infected patients, especially those with certain risk factors such as coinfection with hepatitis B virus (HBV) or hepatitis C virus (HCV), female gender, alcohol abuse, older age, or obesity. Understanding how, when, and why drug-related liver damage occurs is key to managing these patients safely and effectively. Knowledge of HAART-related liver effects will help ensure that patients receive the most benefit with the least toxicity from any given drug regimen. As more information about the mechanisms of drug related liver injury is known, clinicians will be better able to tailor therapies to suit individual situations, resulting in greater patient safety and outcomes.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19211929     DOI: 10.1177/1545109708330906

Source DB:  PubMed          Journal:  J Int Assoc Physicians AIDS Care (Chic)        ISSN: 1545-1097


  10 in total

1.  Management of HIV-1 associated hepatitis in patients with acquired immunodeficiency syndrome: role of a successful control of viral replication.

Authors:  Antonella Esposito; Valentina Conti; Maria Cagliuso; Daniele Pastori; Alessandra Fantauzzi; Ivano Mezzaroma
Journal:  AIDS Res Ther       Date:  2011-03-01       Impact factor: 2.250

Review 2.  Liver disease in the HIV-infected individual.

Authors:  Jennifer C Price; Chloe L Thio
Journal:  Clin Gastroenterol Hepatol       Date:  2010-09-17       Impact factor: 11.382

3.  Antitubercular therapy induced liver function tests abnormalities in human immunodeficiency virus infected individuals.

Authors:  Pankaj Puri; Navjyot Kaur; Sunny Pathania; Sandeep Kumar; P K Sharma; V K Sashindran
Journal:  Med J Armed Forces India       Date:  2017-01-07

4.  Human immunodeficiency virus and liver disease forum 2010: conference proceedings.

Authors:  Kenneth E Sherman; David L Thomas; Raymond T Chung
Journal:  Hepatology       Date:  2011-12       Impact factor: 17.425

5.  Growing older with HIV/AIDS: new public health challenges.

Authors:  Sean Cahill; Robert Valadéz
Journal:  Am J Public Health       Date:  2013-01-17       Impact factor: 9.308

6.  CLINICAL CHARACTERISTICS, OUTCOMES AND RISK FACTORS FOR DEATH AMONG CRITICALLY ILL PATIENTS WITH HIV-RELATED ACUTE KIDNEY INJURY.

Authors:  Leonardo Duarte Sobreira Luna; Douglas de Sousa Soares; Geraldo Bezerra da Silva Junior; Malena Gadelha Cavalcante; Lara Raissa Cavalcante Malveira; Gdayllon Cavalcante Meneses; Eanes Delgado Barros Pereira; Elizabeth De Francesco Daher
Journal:  Rev Inst Med Trop Sao Paulo       Date:  2016-07-11       Impact factor: 1.846

Review 7.  Liver as a target of human immunodeficiency virus infection.

Authors:  Murali Ganesan; Larisa Y Poluektova; Kusum K Kharbanda; Natalia A Osna
Journal:  World J Gastroenterol       Date:  2018-11-14       Impact factor: 5.742

8.  Hepatotoxicity and associated risk factors in HIV-infected patients receiving antiretroviral therapy at Felege Hiwot Referral Hospital, Bahirdar, Ethiopia.

Authors:  Wondemagegn Mulu; Bokretsion Gidey; Ambahun Chernet; Genetu Alem; Bayeh Abera
Journal:  Ethiop J Health Sci       Date:  2013-11

9.  Zidovudine (AZT) and hepatic lipid accumulation: implication of inflammation, oxidative and endoplasmic reticulum stress mediators.

Authors:  Atrayee Banerjee; Mohamed A Abdelmegeed; Sehwan Jang; Byoung-Joon Song
Journal:  PLoS One       Date:  2013-10-11       Impact factor: 3.240

10.  Characteristics of co-infections by HCV and HBV among Brazilian patients infected by HIV-1 and/or HTLV-1.

Authors:  Marcia Moreira; André Ramos; Eduardo M Netto; Carlos Brites
Journal:  Braz J Infect Dis       Date:  2013-09-09       Impact factor: 3.257

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.